Last reviewed · How we verify
MT027 cells suspension
MT027 cells suspension is a Small molecule drug developed by Suzhou Maximum Bio-tech Co., Ltd.. It is currently in Phase 1 development.
MT027 cells suspension is being studied in clinical trials for various conditions, including high-grade glioma, brain cancers, and advanced malignant solid tumors. MT027 cells suspension is classified as a somatic cell supplemental therapy, according to ChEMBL.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MT027 cells suspension |
|---|---|
| Sponsor | Suzhou Maximum Bio-tech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors (PHASE1)
- Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma (PHASE1)
- A Study of MT027 in Patients with Pleural Malignant Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MT027 cells suspension CI brief — competitive landscape report
- MT027 cells suspension updates RSS · CI watch RSS
- Suzhou Maximum Bio-tech Co., Ltd. portfolio CI
Frequently asked questions about MT027 cells suspension
What is MT027 cells suspension?
Who makes MT027 cells suspension?
What development phase is MT027 cells suspension in?
Related
- Manufacturer: Suzhou Maximum Bio-tech Co., Ltd. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing